{"id":25059,"date":"2023-05-18T13:03:42","date_gmt":"2023-05-18T11:03:42","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=25059"},"modified":"2023-05-18T13:03:42","modified_gmt":"2023-05-18T11:03:42","slug":"gyventojams-vaistas-nuo-covid-19","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2023\/05\/18\/gyventojams-vaistas-nuo-covid-19\/","title":{"rendered":"Gyventojams \u2013 vaistas nuo COVID-19"},"content":{"rendered":"<p><strong>Sveikatos apsaugos ministerija informuoja, kad nuo gegu\u017e\u0117s 19 d. gyventojai gali kreiptis \u012f savo \u0161eimos gydytojus d\u0117l valstyb\u0117s biud\u017eeto l\u0117\u0161omis apmok\u0117to ir neatlygintinai i\u0161duodamo registruoto vaisto nuo COVID-19 skyrimo. Vaistai i\u0161duodami vaistini\u0173 tinklo \u201eEurovaistin\u0117\u201c, kuri atsiliep\u0117 \u012f ministerijos kvietim\u0105 prisid\u0117ti prie vaist\u0173 i\u0161davimo, vaistin\u0117se visoje \u0161alyje.<\/strong><\/p>\n<p>Vaistas (veikliosios med\u017eiagos nirmatrelviras ir ritonaviras) skirtas koronaviruso sukeltos ligos gydymui suaugusiesiems, kuriems nereikia papildomos deguonies terapijos ir kuriems kyla didesn\u0117 progresavimo \u012f sunkios eigos COVID-19 rizika. Vaist\u0105 reikia prad\u0117ti vartoti kuo grei\u010diau po COVID-19 diagnoz\u0117s nustatymo ir per 5 paras nuo simptom\u0173 prad\u017eios.<\/p>\n<p>Vaistai skiriami \u012fprasta tvarka i\u0161ra\u0161ant recept\u0105. Gydytojas, prie\u0161 i\u0161ra\u0161ydamas recept\u0105, turi \u012fvertinti, kada pacientui pasirei\u0161k\u0117 COVID-19 ligos simptomai ir atsi\u017evelgiant \u012f tai, kad pacientas turi prad\u0117ti vartoti vaist\u0105 ne v\u0117liau kaip per 5 dienas nuo min\u0117tos ligos simptom\u0173 atsiradimo prad\u017eios, nurodyti ne ilgesn\u012f nei 5 dien\u0173 recepto galiojimo termin\u0105.<\/p>\n<p>Receptiniai vaistai i\u0161duodami \u201eEurovaistini\u0173\u201c tinkle, visose \u0161alies savivaldyb\u0117se, i\u0161 viso 101 vaistin\u0117je. J\u0173 i\u0161sam\u0173 s\u0105ra\u0161\u0105 rasite <a href=\"https:\/\/sam.lrv.lt\/uploads\/sam\/documents\/files\/KORONA\/Vaistini%C5%B3%20s%C4%85ra%C5%A1as.xlsx\" target=\"_blank\" rel=\"noopener\">\u010cIA<\/a>.<\/p>\n<p>Lietuva vaist\u0105 \u012fsigijo per Europos Komisijos (EK) bendruosius vakcin\u0173 ir kit\u0173 vaist\u0173 nuo COVID-19 ligos profilaktikos ir gydymo pirkimus. EK organizuojami COVID-19 vaist\u0173 pirkimai pad\u0117jo i\u0161sider\u0117ti geresnes pirkimo s\u0105lygas ir stabil\u0173 tiekim\u0105 valstyb\u0117ms nar\u0117ms.<\/p>\n<p>I\u0161 viso per du kartus \u012fsigyta 13 t\u016bkst. vaisto pakuo\u010di\u0173, i\u0161 kuri\u0173 did\u017eioji dalis bus i\u0161duota gyventojams vaistin\u0117se pagal receptus, likusi \u2013 aktyviam gydymui \u0161alies gydymo \u012fstaigose.<\/p>\n<p><a href=\"https:\/\/sam.lrv.lt\/lt\/kontaktai-ziniasklaidai\" target=\"_blank\" rel=\"noopener\"><em>SAM Komunikacijos skyrius<\/em><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sveikatos apsaugos ministerija informuoja, kad nuo gegu\u017e\u0117s 19 d. gyventojai gali kreiptis \u012f savo \u0161eimos gydytojus d\u0117l valstyb\u0117s biud\u017eeto l\u0117\u0161omis apmok\u0117to ir neatlygintinai i\u0161duodamo registruoto vaisto nuo COVID-19 skyrimo. Vaistai i\u0161duodami vaistini\u0173 tinklo \u201eEurovaistin\u0117\u201c, kuri atsiliep\u0117 \u012f ministerijos kvietim\u0105 prisid\u0117ti prie vaist\u0173 i\u0161davimo, vaistin\u0117se visoje \u0161alyje. Vaistas (veikliosios med\u017eiagos nirmatrelviras ir ritonaviras) skirtas koronaviruso sukeltos&hellip;<\/p>","protected":false},"author":3,"featured_media":25060,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[6],"tags":[],"class_list":["post-25059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-naujienos","category-6","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-6wb","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2023\/05\/21441_cec81f491e827418037fbe70158b9726.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/25059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=25059"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/25059\/revisions"}],"predecessor-version":[{"id":25061,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/25059\/revisions\/25061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/25060"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=25059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=25059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=25059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}